Escape of HIV-1 Envelope Glycoprotein from Restriction of Infection by IFITM3

被引:12
作者
Drouin, Aurelie [1 ,2 ]
Migraine, Julie [1 ,2 ]
Durand, Marie-Alice [1 ,2 ]
Moreau, Alain [1 ,2 ]
Burlaud-Gaillard, Julien [1 ,2 ,3 ]
Beretta, Maxime [1 ,2 ,4 ]
Roingeard, Philippe [1 ,2 ,3 ]
Bouvin-Pley, Melanie [1 ,2 ]
Braibant, Martine [1 ,2 ]
机构
[1] Univ Tours, Tours, France
[2] CHRU Tours, INSERM, U1259, Tours, France
[3] CHRU Tours, Plateforme IBiSA Microscopie Elect, Tours, France
[4] Inst Pasteur, Dept Immunol, Lab Humoral Immunol, Paris, France
关键词
IFITM3; envelope glycoprotein; human immunodeficiency virus; restriction factor; IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN MONOCLONAL-ANTIBODY; INFLUENZA-A VIRUS; WEST NILE VIRUS; PROTEINS; BROAD; NEUTRALIZATION; GP41; INHIBITION; RESISTANCE;
D O I
10.1128/JVI.01994-20
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Interferon-induced transmembrane protein 3 (IFITM3) is a cellular factor that reduces HIV-1 infectivity by an incompletely understood mechanism. We show here that viruses differing only in the envelope glycoprotein (Env) expressed on their surface have different sensitivities to IFITM3. Measurements of the sensitivity of viruses to neutralizing antibodies showed that IFITM3 increased the sensitivity of IFITM3-sensitive viruses to PG16, which targets the V1V2 loop, suggesting that IFITM3 promotes exposure of the PG16 epitope of IFITM3-sensitive viruses. Exchanges of V1V2 loops between the Env proteins of sensitive and resistant viruses revealed that V1V2 and V3 act together to modulate viral sensitivity to IFITM3. Coimmunoprecipitation experiments showed that IFITM3 interacted with both the precursor (gp160) and cleaved (gp120) forms of Env from IFITM3-sensitive viruses but with only the precursor (gp160) form of Env from IFITM3-resistant viruses. This finding suggests that the interaction between the Env protein of resistant viruses and IFITM3 was inhibited once Env had been processed in the Golgi apparatus. This hypothesis was supported by immunofluorescence experiments, which showed a strong colocalization of IFITM3 with Env of sensitive viruses, but only weak colocalization with Env of resistant viruses on the plasma membrane of virus-producing cells. Together, these results indicate that IFITM3 interacts with Env, inducing conformational changes that may decrease viral infectivity. This antiviral action is, nevertheless, modulated by the nature of Env, in particular its V1V2 and V3 loops, which after maturation may be able to escape this interaction. IMPORTANCE Interferon-induced transmembrane protein 3 (IFITM3) is a cellular factor that reduces HIV-1 infectivity by an incompletely understood mechanism. This study aimed to elucidate the role of the HIV-1 envelope glycoprotein (Env) in determining viral susceptibility to IFITM3. We found that viruses differing only in Env expressed on their surface had different sensitivities to IFITM3. By comparing the Env proteins of viruses that were highly sensitive or resistant to IFITM3, we obtained new insight in the mechanisms by which HIV-1 escapes this protein. We showed that IFITM3 interacts with the Env protein of sensitive viruses in virion-producing cells, inducing conformational changes that may decrease viral infectivity. However, this antiviral action is modulated by the nature of Env, particularly the V1V2 and V3 loops, which may be able to escape this interaction after processing in the Golgi apparatus.
引用
收藏
页数:18
相关论文
共 50 条
[41]   Human IFITM3 restricts chikungunya virus and Mayaro virus infection and is susceptible to virus-mediated counteraction [J].
Franz, Sergej ;
Pott, Fabian ;
Zillinger, Thomas ;
Schueler, Christiane ;
Dapa, Sandra ;
Fischer, Carlo ;
Passos, Vania ;
Stenzel, Saskia ;
Chen, Fangfang ;
Doehner, Katinka ;
Hartmann, Gunther ;
Sodeik, Beate ;
Pessler, Frank ;
Simmons, Graham ;
Drexler, Jan Felix ;
Goffinet, Christine .
LIFE SCIENCE ALLIANCE, 2021, 4 (07)
[42]   Relationship of HIV-1 and SIV envelope glycoprotein trimer occupation and neutralization [J].
Crooks, Emma T. ;
Jiang, Pengfei ;
Franti, Michael ;
Wong, Sharon ;
Zwick, Michael B. ;
Hoxie, James A. ;
Robinson, James E. ;
Moore, Penny L. ;
Binley, James M. .
VIROLOGY, 2008, 377 (02) :364-378
[43]   Contribution of the HIV-1 Envelope Glycoprotein to AIDS Pathogenesis and Clinical Progression [J].
Valenzuela-Fernandez, Agustin ;
Cabrera-Rodriguez, Romina ;
Casado, Concha ;
Perez-Yanes, Silvia ;
Pernas, Maria ;
Garcia-Luis, Jonay ;
Marfil, Silvia ;
Olivares, Isabel ;
Estevez-Herrera, Judith ;
Trujillo-Gonzalez, Rodrigo ;
Blanco, Julia ;
Lopez-Galindez, Cecilio .
BIOMEDICINES, 2022, 10 (09)
[44]   Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms [J].
Brouwer, Philip J. M. ;
Sanders, Rogier W. .
CURRENT OPINION IN HIV AND AIDS, 2019, 14 (04) :302-308
[45]   HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies [J].
Sliepen, Kwinten ;
Sanders, Rogier W. .
EXPERT REVIEW OF VACCINES, 2016, 15 (03) :349-365
[46]   Clinical evaluation of a soluble trimeric HIV-1 envelope glycoprotein vaccine [J].
Sanders, Rogier W. .
EXPERT REVIEW OF VACCINES, 2011, 10 (08) :1117-1120
[47]   Stabilizing the HIV-1 Envelope Glycoprotein State 2A Conformation [J].
Vezina, Dani ;
Gong, Shang Yu ;
Tolbert, William D. ;
Ding, Shilei ;
Nguyen, Dung ;
Richard, Jonathan ;
Gendron-Lepage, Gabrielle ;
Melillo, Bruno ;
Smith, Amos B., III ;
Pazgier, Marzena ;
Finzi, Andres .
JOURNAL OF VIROLOGY, 2021, 95 (05)
[48]   Effects of Adjuvants on HIV-1 Envelope Glycoprotein SOSIP Trimers In Vitro [J].
Ozorowski, Gabriel ;
Cupo, Albert ;
Golabek, Michael ;
LoPiccolo, Michelle ;
Ketas, Thomas A. ;
Cavallary, Matt ;
Cottrell, Christopher A. ;
Klasse, P. J. ;
Ward, Andrew B. ;
Moore, John P. .
JOURNAL OF VIROLOGY, 2018, 92 (13)
[49]   Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens [J].
Thijs van Montfort ;
Mark Melchers ;
Tony MM van Capel ;
Ester C de Jong ;
William A Paxton ;
Rogier W Sanders .
Retrovirology, 8 (Suppl 2)
[50]   The Variable Loop 3 in the Envelope Glycoprotein Is Critical for the Atypical Coreceptor Usage of an HIV-1 Strain [J].
Xiang, Yue ;
Liu, Wei ;
Chen, Yue ;
Zhang, Chuntao ;
Su, Weiheng ;
Zhang, Yan ;
Sun, Jiaxi ;
Gao, Feng ;
Jiang, Chunlai .
PLOS ONE, 2014, 9 (06)